In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.

Current therapy of Entamoeba histolytica infection requires use of multiple agents effective at different body sites, including the intestinal lumen, intestinal tissue, and liver. Azithromycin and CP-63,956, new extended-half-life macrolides which reach high levels in tissue, exhibit in vitro antiam...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Ravdin, J I, Skilogiannis, J
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 1989
Matèries:	Research Article
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC284263/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2548442/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.33.6.960
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!